Anumana adds two directors to board amid commercial expansion

Anumana Inc., an AI-powered cardiovascular detection company, appointed Kevin Ballinger and Jean-Luc Butel to its board of directors, according to a company statement.

Ballinger brings experience from the medtech and life sciences sectors. He currently serves on CVRx's board and previously served as Chief Executive Officer of Aldevron, LLC, which Danaher Corporation acquired in 2021. He spent 25 years at Boston Scientific Corporation, including nine years as Executive Vice President and Global President of the Interventional Cardiology division.

Butel serves on multiple healthcare company boards including Takeda Pharmaceutical Company, ICON, and Rani Therapeutics. He previously held executive positions at Baxter International and Medtronic, and served as a senior advisor to McKinsey's Healthcare Practice.

"Kevin and Jean-Luc bring a depth of experience that will be an asset to Anumana," said Maulik Nanavaty, CEO of Anumana. "Their decades of diverse and extensive understanding of healthcare organizations will help guide us as we move into our next phase of growth and expand the commercialization of cardiovascular deep learning AI solutions and product offerings."

The Cambridge, Massachusetts-based company was co-founded by nference and Mayo Clinic. Anumana develops software-as-a-medical-device solutions that apply AI to cardiovascular care, including ECG-based algorithms and imaging applications.

The company's FDA-cleared ECG-AI LEF algorithm became available in the U.S. and eligible for reimbursement as of January 2025.

You May Also Be Interested In

• Altria adds Refresco CEO Steve Presley to its board
• Daré Bioscience gets $908K NIH grant for preterm birth program
• Yum! Brands adds Bratspies to board committee